Batu Biologics Appoints Biotechnology Industry Veteran, Dr. Alan Lewis, to Scientific Advisory Board
Former CEO of Medistem to Assist in the FDA Development of the First Anti-Angiogenic Cancer Vaccine for Lung Cancer
SAN DIEGO--(BUSINESS WIRE)--Batu Biologics announced today the appointment of Dr. Alan Lewis to the company’s Scientific Advisory Board, an experienced industry veteran with over 37 years of experience as an executive in life sciences. Dr. Lewis spent 15 years at the pharmaceutical company Wyeth-Ayerst, where he was Vice President of Research, leading translational research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy and bone metabolism diseases. He later became the CEO of Signal Pharmaceuticals, a company focusing on small-molecule drug discovery and development, which was eventually acquired by Celgene in 2010. Subsequent to his employment as President of Celgene, Dr. Lewis had several successful business ventures including raising $27 million as CEO of Novocell, becoming the CEO of the Juvenile Diabetes Research Foundation, and raising over $45 million as CEO of Ambit.
“The Batu Biologics Team is extremely excited to have Dr. Alan Lewis on board to assist with the development and commercialization of ValloVaxTM”
“The Batu Biologics Team is extremely excited to have Dr. Alan Lewis on board to assist with the development and commercialization of ValloVaxTM,” said Samuel C. Wagner, President and CEO of Batu Biologics. “We believe Dr. Lewis’ extensive experience in strategic development as well as his astonishing track record will not only help facilitate the expedited growth of our company, but also bring many new eyes to our cause.”
“It is my honor to continue working with Dr. Lewis. In our previous work at Medistem Inc, the recruitment of Dr. Lewis was a pivotal event that led to the $26 million dollar acquisition of our company. We anticipate expanding on this success at Batu Biologics,” said Thomas Ichim, Chairman of Batu Biologics and former President of Medistem Inc.
“The concept of immunologically targeting the 'Achilles Heel' of the tumor, by inducing the immune response to kill blood vessels that feed the tumor, is novel and promising. I look forward to working with Mr. Wagner and the team at Batu Biologics at developing a new weapon in the fight against cancer,” said Dr. Lewis.
Earlier this month, Batu Biologics announced efforts to raise $100,000 through donation-based crowd funding to support completion of the company’s preclinical research in preparation of the filing of an Investigational New Drug (IND) application to the FDA. Link to the campaign: https://www.indiegogo.com/projects/emerging-lung-cancer-vaccine-targets-tumor-blood-vessels-introducing-vallovax
About Batu Biologics
Founded in 2013, Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. The company’s products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem and Vallovax. With the recent successes of immunotherapy in a variety of tumors, Batu Biologics believes there is an increasing unmet need for non-toxic immune modulators that can augment efficacy of existing therapeutics. Our team is motivated to bring novel therapeutics to the forefront of medical research that use the power of the body’s own immune system to extend life expectancy. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP in 2014.
9255 Towne Centre Drive
San Diego, CA 92121
Janssen Research and Development
3210 Merryfield Row
San Diego, CA 92121